OTHER GROUP COMPANIES
market

Lupin receives USFDA approval for Paliperidone Extended-Release Tablets

Lupin receives USFDA approval for Paliperidone Extended-Release Tablets

July 01, 2022 3:48 IST | capital market
Lupin announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, and 9 mg, to market a generic equivalent of Invega? Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development, LLC. The product will be manufactured at Lupins facility in Goa, India. Paliperidone Extended-Release Tablets (RLD Invega?) had estimated annual sales of USD 152 million in the U.S. (IQVIA MAT March 2022). Powered by Capital Market - Live News

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity